Wednesday 2/11 Insider Buying Report: BMI, ROP

Badger Meter CEO Kenneth Bockhorst bought 3,300 shares of BMI at $152.42 each for $502,986, a purchase reported as his first insider filing in 12 months; Badger Meter shares were up ~3.5% on Wednesday. Separately, Thomas Patrick Joyce Jr. bought 1,400 Roper Technologies shares at $358.46 each for $501,844 (his first insider filing in 12 months); Roper was down ~3.8% on Wednesday and traded intraday as low as $333.96, about 6.8% below Joyce Jr.’s purchase price. These insider buys signal management confidence but are relatively modest in size and unlikely to be materially market-moving on their own.

Analysis

Market structure: Two small-to-mid cap names (BMI, ROP) see coordinated ~ $0.5m insider buys that create short-term buy pressure (BMI +3.5% intraday). Direct winners are current long holders and near-term momentum traders; short sellers face squeeze risk for 1–5 trading days if follow-through buying occurs. Pricing power/market share unaffected materially — these are signal trades, not new fundamentals, so supply/demand impact is localized to free float and short-interest dynamics.

Risk assessment: Tail risks include macro-driven capex collapse (industrial orders down >15% YoY) or a Fed shock that re-rates ROP’s long-duration cash flows; operational/regulatory risks are idiosyncratic but low probability. Immediate (days) effect = headline-driven volatility ±5–8%; short-term (weeks–months) depends on earnings/order-book updates; long-term (quarters–years) reverts to fundamentals (revenue/CPS growth, margin resilience). Hidden dependencies: insider buys may follow option exercises or pre-scheduled plans—verify Form 4 pattern; catalysts include earnings (next 30–90 days), PMI/capex prints and rate shifts.

Trade implications: Tactical direct plays — small conviction longs: BMI > buy on dips < $155 with 3–6 month target +10–15%, stop < $140; ROP — opportunistic buy under $340 with 3–6 month target +8–12%, use downside protection. Options: consider 3–6 month call spreads to cap cost (e.g., BMI 155/175, ROP 340/380) or buy 10% OTM puts as stop-loss if delta-hedged. Pair trade: long BMI (2–3% portfolio) vs short ROP (1–2%) to isolate hardware vs software/recur rev multiple compression.

Contrarian angles: Consensus treats both buys as bullish; missing is scale—$0.5m buys are modest vs market caps and can be token. Reaction may be overdone for ROP where price dipped ~6.8% below insider price; that creates a short-term buying window rather than a conviction entry. Historical parallels: insider buys during minor pullbacks (2015–2022) often precede 8–20% mean reversion inside 3–6 months, but about 20% were hedged/option-driven — confirm non-derivative purchases to avoid false signals.

Key Decisions for Investors

• Establish a 2–3% long position in BMI (ticker: BMI) on a pullback to <$155; target +10–15% over 3–6 months, place a stop-loss at $140 (≈8% downside) and trim half at +10%.
• Initiate a tactical 1–2% long in ROP if price trades below $340; hedge with a 3-month 10% OTM protective put or purchase a 3–6 month 340/380 call spread to cap premium and aim for +8–12% upside.
• Implement a relative-value pair: long BMI 2% vs short ROP 1% to express a view that industrial instrumentation will re-rate faster than higher-multiple software/asset-heavy ROP over 3–6 months; rebalance if spread moves >10% against position.
• Before increasing allocations, verify Form 4 details within 48 hours to confirm open-market purchase (not option exercise or rule 10b5-1); if purchases are derivative-funded, reduce position sizes by 50% and wait for earnings/PMI prints within 30–60 days.